Page last updated: 2024-11-02

pirbuterol and Cardiac Failure

pirbuterol has been researched along with Cardiac Failure in 29 studies

pirbuterol: structure

Research Excerpts

ExcerptRelevanceReference
"Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties."9.05Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981)
"In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment."9.05Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983)
"The metabolic, hormonal and haemodynamic effects of oral pirbuterol, a new beta 2-adrenoceptor agonist, were studied acutely (n = 19) and after 3 months treatment (n = 11) in patients with severe heart failure receiving chronic frusemide therapy."7.67Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. ( Canepa-Anson, R; Cockrill, B; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1987)
"We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure."7.66Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981)
"Fourteen patients with refractory congestive heart failure (CHF) were given a single oral dose ranging from 5 to 30 mg of the new sympathomimetic drug pirbuterol."7.66Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. ( Asinger, RW; Cohn, JN; Francis, GS; Hoback, J; Hodges, M; Sharma, B; Taylor, CR, 1981)
"An open study of long term treatment with an oral beta 2 agonist (pirbuterol 20 mg three times daily) was undertaken in 63 patients with severe chronic heart failure."7.66Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. ( Canepa-Anson, R; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983)
"Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized."7.66Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981)
" To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients."6.65Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982)
"Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours."6.65Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983)
"The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management."6.15Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. ( Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR, 1981)
"Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties."5.05Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981)
"In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment."5.05Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983)
"This study was designed to investigate and compare the haemodynamic and metabolic responses to pirbuterol and salbutamol in patients with congestive heart failure and coronary artery disease."5.05Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study. ( Bergman, G; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984)
"The metabolic, hormonal and haemodynamic effects of oral pirbuterol, a new beta 2-adrenoceptor agonist, were studied acutely (n = 19) and after 3 months treatment (n = 11) in patients with severe heart failure receiving chronic frusemide therapy."3.67Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. ( Canepa-Anson, R; Cockrill, B; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1987)
"We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure."3.66Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981)
"Fourteen patients with refractory congestive heart failure (CHF) were given a single oral dose ranging from 5 to 30 mg of the new sympathomimetic drug pirbuterol."3.66Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. ( Asinger, RW; Cohn, JN; Francis, GS; Hoback, J; Hodges, M; Sharma, B; Taylor, CR, 1981)
"An open study of long term treatment with an oral beta 2 agonist (pirbuterol 20 mg three times daily) was undertaken in 63 patients with severe chronic heart failure."3.66Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. ( Canepa-Anson, R; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983)
"Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized."3.66Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981)
" To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients."2.65Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982)
"Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours."2.65Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983)
"Amrinone appears to be a promising agent for the long-term treatment of chronic cardiac failure; the utility of pirbuterol, an oral catecholamine analog, remains to be determined."1.26Cardiotonic agents in the management of chronic cardiac failure. ( Andrews, V; Janicki, JS; Weber, KT, 1982)
"Modern management of congestive heart failure (CHF) employs inotropic drugs, vasodilators, and diuretics."1.26Problems in assessment of new pharmacologic agents for the heart failure patient. ( Benotti, JR; Braunwald, E; Carabello, BA; Colucci, WS; Grossman, W; Malacoff, R; Rude, RE; Wynne, J, 1981)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-199029 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sharpe, DN1
Dawson, JR6
Canepa-Anson, R7
Kuan, P6
Whitaker, NH1
Carnie, J1
Warnes, C1
Reuben, SR5
Poole-Wilson, PA7
Sutton, GC7
Colucci, WS4
Alexander, RW2
Williams, GH1
Rude, RE4
Holman, BL2
Konstam, MA1
Wynne, J3
Mudge, GH3
Braunwald, E3
Sharma, B1
Hoback, J1
Francis, GS1
Hodges, M1
Asinger, RW1
Cohn, JN1
Taylor, CR5
Grossman, W3
Warnes, CA1
Gold, FL1
Horwitz, LD1
Weber, KT2
Andrews, V2
Janicki, JS2
Likoff, M1
Reichek, N1
Bijak, A1
Czołpiński, T1
Frankl, WS1
Reuben, S2
Bayliss, J2
Norell, MS1
Smiseth, OA1
Pamelia, FX1
Gheorghiade, M1
Beller, GA1
Bishop, HL1
Olukotun, AY2
Watson, DD1
Grunwald, AM1
Sirowatka, J1
Carabello, BA2
Timmis, AD1
Bergman, G1
Walker, L1
Monaghan, MJ1
Jewitt, DE1
Norell, M1
Rae, AP1
Tweddel, AC1
Hutton, I1
Awan, NA4
Needham, K2
Evenson, MK4
Mason, DT4
Baird, JR1
Blackburn, KJ1
Cambridge, D1
Constantine, JW1
Ghaly, MS1
Hayden, ML1
McIlhenny, HM1
Moore, PF1
Pullman, LG1
Salsburg, DS1
Saxton, CA1
Shevde, S1
Turi, Z1
Brown, EJ1
Lorell, BH1
Hermanovich, J2
Joye, JA1
DeMaria, AN1
Benotti, JR1
Malacoff, R1
Needham, KE2
Evans, TO1
Amsterdam, E1
Vahanian, A1
Le Potier, J1
Sergent, J1
Michel, PL1
Acar, J1
Uretsky, BF1
Cockrill, B1

Reviews

4 reviews available for pirbuterol and Cardiac Failure

ArticleYear
Newer inotropic agents.
    Methods and findings in experimental and clinical pharmacology, 1984, Volume: 6, Issue:4

    Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Dobutamine; Ethanolamines; Heart Failure; Humans; Prac

1984
[New drugs with positive inotropic action].
    Kardiologia polska, 1982, Volume: 25, Issue:4

    Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease;

1982
Beta 2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias.
    European heart journal, 1982, Volume: 3 Suppl D

    Topics: Adrenergic beta-Agonists; Albuterol; Arrhythmias, Cardiac; Blood Glucose; Epinephrine; Ethanolamines

1982
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr

1981

Trials

6 trials available for pirbuterol and Cardiac Failure

ArticleYear
Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.
    British medical journal (Clinical research ed.), 1981, May-02, Volume: 282, Issue:6274

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Chronic Disease; Ethanolamines; Female;

1981
Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure.
    Circulation, 1982, Volume: 66, Issue:6

    Topics: Adrenergic beta-Agonists; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Dose-Response Relation

1982
Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
    American heart journal, 1983, Volume: 106, Issue:6

    Topics: Administration, Oral; Adult; Aged; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic;

1983
Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study.
    International journal of cardiology, 1984, Volume: 5, Issue:3

    Topics: Adult; Aged; Albuterol; Blood Glucose; Ethanolamines; Fatty Acids, Nonesterified; Female; Heart Fail

1984
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
    British heart journal, 1983, Volume: 49, Issue:3

    Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Drug Therapy, Combinatio

1983
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr

1981

Other Studies

20 other studies available for pirbuterol and Cardiac Failure

ArticleYear
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
    The New England journal of medicine, 1981, Jul-23, Volume: 305, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Chronic Disease; Drug Tolerance; Ethanolamine

1981
Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Dose-Response Relat

1981
Acute and chronic effects of pirbuterol on left ventricular ejection fraction and clinical status in severe congestive heart failure.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Adrenergic beta-Agonists; Arrhythmias, Cardiac; Cardiac Output; Drug Evaluation; Ethanolamines; Hear

1981
Single-dose and dose-response studies with oral pirbuterol, a new beta agonist in chronic heart failure.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Dose-Response Relat

1981
Hemodynamic effects of pirbuterol in conscious dogs.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiac Pacing, Artificial; Dogs; Et

1981
Clinical studies with beta 2 adrenoceptor agonists in heart failure.
    European heart journal, 1982, Volume: 3 Suppl D

    Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Ethanolamines; He

1982
Effects of the beta-adrenergic receptor agonist pirbuterol on cardiac performance during acute ischaemic left ventricular failure in dogs.
    European journal of pharmacology, 1983, Mar-04, Volume: 87, Issue:4

    Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Coronary Disease; Dogs; Ethanolamines; Fatty Acid

1983
Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol.
    British heart journal, 1983, Volume: 50, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Aged; Cardiotonic Agents; Ethanolamines; Female; Heart Failure; Hem

1983
Beta-agonists and heart failure.
    Lancet (London, England), 1983, Nov-05, Volume: 2, Issue:8358

    Topics: Adrenergic beta-Agonists; Ethanolamines; Heart Failure; Hemodynamics; Humans

1983
The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
    Herz, 1983, Volume: 8, Issue:1

    Topics: Catecholamines; Dobutamine; Dopamine; Ethanolamines; Heart Failure; Hemodynamics; Humans; Practolol;

1983
Management of severe chronic CHF with oral pirbuterol.
    Acta medica Scandinavica. Supplementum, 1981, Volume: 652

    Topics: Cardiac Catheterization; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Heart F

1981
Cardiotonic agents in the management of chronic cardiac failure.
    American heart journal, 1982, Volume: 103, Issue:4 Pt 2

    Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dobutamin

1982
Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure.
    Circulation, 1981, Volume: 64, Issue:1

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Coronary Disease; Ethanolamines; Heart

1981
Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Administration, Oral; Adult; Cardiotonic Agents; Dobutamine; Drug Evaluation; Drug Therapy, Combinat

1981
Problems in assessment of new pharmacologic agents for the heart failure patient.
    American heart journal, 1981, Volume: 102, Issue:3 Pt 2

    Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Cardiovascular Agents; Drug Evaluation; Energy Metabol

1981
Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.
    Circulation, 1981, Volume: 63, Issue:1

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Fem

1981
Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure.
    The American journal of cardiology, 1981, Volume: 47, Issue:3

    Topics: Blood Pressure; Cardiac Output; Cardiotonic Agents; Catecholamines; Dobutamine; Ethanolamines; Femal

1981
[Positive inotropic agents. Generalities and classification].
    Annales de medecine interne, 1985, Volume: 136, Issue:3

    Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Calcium; Cardiotonic Agents; Digitalis Glycoside

1985
Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
    Postgraduate medical journal, 1986, Volume: 62, Issue:728

    Topics: Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Enoximone; Ethanolamines; Heart; Heart Failure; H

1986
Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.
    British journal of clinical pharmacology, 1987, Volume: 23, Issue:2

    Topics: Adult; Aged; Blood Glucose; Ethanolamines; Fasting; Fatty Acids, Nonesterified; Female; Heart Failur

1987